세계의 인간성장호르몬(HGH) 시장 규모 및 예측(2025-2033년)
인간성장호르몬(HGH) 시장은 2024년 70억 8,000만 달러에서 2033년까지 168억 6,000만 달러에 달할 것으로 예상됩니다. 이 증가는 2025-2033년 CAGR이 10.12%인 것으로 나타났습니다. 이러한 성장의 원동력은 HGH에 대한 인식의 증가, 성장 장애의 증가, 생명공학의 발달로 인한 치료 및 시장 기회의 증가입니다.
세계 인간성장호르몬(HGH) 시장 전망
인간성장호르몬(HGH)은 뇌하수체에서 분비되는 펩타이드 호르몬으로 성장, 대사, 세포 재생을 관장합니다. 소아기 성장에 중요하며, 키와 근육에 영향을 미치고, 성인에서도 골밀도와 체성분 등 여러 신체 기능에 영향을 미칩니다.
지난 10년간 HGH는 노화 방지 효과가 있는 것으로 알려지면서 점점 더 인기를 얻고 있으며, 건강 증진, 근육량 증가, 체지방 감소를 위해 HGH를 사용하기 시작하는 사람들도 있습니다. HGH는 운동선수나 보디빌더들이 경기력 향상을 위해 남용하는 경우도 있습니다.
HGH의 의학적 용도는 어린이의 성장 장애와 성인의 호르몬 결핍을 치료하는 것입니다. 그러나 남용은 관절통, 인슐린 저항성, 질병에 대한 취약성 증가 등 심각한 부작용을 유발할 수 있습니다. HGH의 위험성에 대한 인식이 높아짐에 따라 HGH의 책임감 있는 윤리적 사용에 초점을 맞추고 효과적인 치료적 사용을 위한 효과적인 의료 모니터링에 초점을 맞춘 노력이 계속되고 있습니다.
인간성장호르몬 시장의 성장 촉진요인
성장호르몬 결핍증 증가
hGH 시장의 주요 성장 촉진요인 중 하나는 성장호르몬 결핍증(GHD), 터너 증후군, 만성 신부전증과 같은 성장 장애의 유병률 증가입니다. 호르몬 결핍이 있는 어린이와 성인은 정상적인 성장, 신진대사, 건강 유지를 위해 지속적인 hGH 치료가 필요합니다. 첨단 유전학적 검사와 내분비학적 검사를 통한 조기 발견이 환자 식별을 더욱 용이하게 하고 있습니다. 의료진과 부모들의 인식이 높아짐에 따라 hGH 치료를 받는 사람들도 늘어나고 있습니다. 치료적 개입에 대한 수요 증가는 세계 인간성장호르몬 시장의 성장에 직접적으로 기여하고 있습니다. NCBI에 따르면, 소아 성장호르몬 결핍증은 영국에서 약 3,500-4,000명당 1명꼴로 진단되고 있습니다. 또한, 성장호르몬 시장은 이 부문에서 진행 중인 지속적인 연구 개발 프로세스로 인해 성장세를 보이고 있습니다. 예를 들어, 2022년 2월, OPKO와 화이자는 유럽연합으로부터 소아 성장호르몬 결핍증 치료에 사용되는 주 1회 투여하는 NGENLA(somatrogon) 주사제의 판매 승인을 받았습니다.
약물전달 기술 개발
약물전달 기술의 발전은 hGH 시장에 큰 영향을 미치고 있습니다. 기존에는 매일 주사로 투여하던 성장호르몬 치료는 현재 환자의 순응도를 높이기 위해 장시간 작용하는 제제, 바늘이 없는 주사기, 펜형 장치로 전환되고 있습니다. 피하주사용 자가주사기는 사용이 간편하고 불편함이 적어 점점 더 많은 인기를 얻고 있습니다. 또한, 투여 횟수를 줄이고 치료의 편의성을 높이기 위해 각사는 서방형 제제에 투자하고 있습니다. 이러한 개발은 소아 환자의 순응도를 높일 뿐만 아니라 성인에게도 적용되어 국제 의료 시장에서 hGH 치료의 보급을 더욱 촉진하고 있습니다. 2023년 8월, FDA는 Opko Health, Inc.와 Pfizer의 소아 성장호르몬 결핍증에 대한 주 1회 투여용 somatrogon을 승인했습니다. 장기 지속형 주사제인 Somatrogon-ghla(Ngenla)는 3상 임상시험 데이터에 따르면, 연간 신장 성장 속도에서 somatropin 대비 비열등성을 보였습니다. 소마트로핀과 동등한 안전성 프로파일을 가진 이번 승인은 혁신적인 치료 옵션을 통해 성장 장애 치료에 대한 소아 환자들의 요구에 부응하고자 하는 Opko Health와 화이자의 헌신적인 노력을 뒷받침하는 것입니다.
세계의 인간성장호르몬(HGH) 시장에 대해 조사했으며, 성장 촉진요인 및 과제, 각 부문별 분석, 주요 기업 분석 등의 정보를 전해드립니다.
Global Human Growth Hormone (HGH) Market Size & Forecast 2025-2033
Human Growth Hormone (HGH) market is expected to expand tremendously, with an estimated growth to US$ 16.86 billion by the year 2033 from US$ 7.08 billion in 2024. This increase represents a compound annual growth rate (CAGR) of 10.12% between 2025 and 2033. The growth is fueled by growing HGH awareness, elevated growth disorders, and development in biotechnology, which improves treatment and market opportunities.
Global Human Growth Hormone (HGH) Market Report by Application (Growth Hormone (GH) Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Prader-Willi Syndrome (PWS), Small for Gestational Age, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Route of Administration (Intravenous, Intramuscular, Subcutaneous, Oral), Countries and Company Analysis, 2025-2033.
Global Human Growth Hormone (HGH) Market Outlook
Human Growth Hormone (HGH) is a peptide hormone secreted by the pituitary gland that is responsible for growth, metabolism, and regeneration of cells. It is important in childhood development, influencing height and muscling, and still affects multiple body functions in adults, including bone density and body composition.
Over the past decade, HGH has become increasingly popular for its supposed anti-aging effects, and some individuals have started using it to increase fitness, muscle mass, and decrease body fat. It is also abused by sports persons and bodybuilders to improve performance, even though there are strict laws against it in professional sports.
Medical applications of HGH are in the treatment of growth disorders in children and hormone deficiencies in adults. Misuse, though, can result in tremendous side effects, such as joint pains, insulin resistance, and enhanced disease vulnerability. As awareness of its risks increases, the effort continues to focus on effective medical oversight for valid therapeutic uses with a focus on using HGH responsibly and ethically.
Growth Drivers in the Human Growth Hormone Market
Growing Incidence of Growth Hormone Deficiencies
One of the key growth drivers of the hGH market is the growing incidence of growth disorders like growth hormone deficiency (GHD), Turner syndrome, and chronic renal insufficiency. Hormone-deficient children and adults need constant hGH therapy to help them grow normally, metabolize, and stay healthy. Early identification through the use of advanced genetic and endocrine testing is further fueling patient identification. With increased awareness among health practitioners and parents, increased numbers are being treated with hGH. Increased demand for therapeutic intervention directly contributes to global human growth hormone market growth. As per NCBI, pediatric growth hormone deficiency are diagnosed in about 1 in every 3,500-4,000 children in the UK. Further, the growth hormone market is also witnessing growth because of continuous research and development processes going on in this sector. For instance, in February 2022, OPKO and Pfizer received marketing authorization from the European Union for its Once-Weekly NGENLA (somatrogon) Injection, utilized in treating pediatric growth hormone deficiency.
Technological Developments in Drug Delivery
Technological advancements in drug delivery are heavily impacting the hGH market. Classically delivered through daily injections, growth hormone treatment is now moving towards long-duration formulations, needle-free injectors, and pen devices aimed at enhancing patient compliance. Auto-injectors for subcutaneous injections are becoming increasingly popular because of ease of use and less discomfort. Companies are also investing in sustained-release formulations to decrease dosing frequency and enhance convenience in treatment. These developments not only enhance compliance among pediatric patients but also boost acceptance in adults, further enhancing the penetration of hGH therapy in international healthcare markets. August 2023, FDA granted Opko Health, Inc. and Pfizer's once-weekly somatrogon approval for pediatric growth hormone deficiency, major players are tactically deepening their market presence. The long-acting injectable Somatrogon-ghla (Ngenla) shows noninferiority to somatropin in enhancing annual height velocity according to data from phase 3 trials. With a comparable safety profile to somatropin, this approval supports Opko Health and Pfizer's dedication to meeting children's need for growth failure treatment with innovative therapeutic options.
Widening Applications Beyond Pediatrics
Although hGH has been used conventionally among pediatric patients, its use in adults is increasing rapidly. Adult growth hormone deficiency, hormonal decline due to age, and off-label uses in metabolic disorders are widening the therapeutic applications of hGH. Research also shows promise in muscle wasting with HIV/AIDS and enhancing bone density. Growing approvals for use in adults and increasing health expenditures are driving adoption. With aging populations in developed nations, adult growth hormone therapy demand is expanding, offering new opportunities for pharmaceutical firms in the hGH market.
Challenges in the Human Growth Hormone Market
High Cost of Therapy
High expense of human growth hormone treatment is the principal barrier to access, especially in middle- and low-income nations. Most patients need long-term treatment, which can be as high as thousands of dollars per year. Even with insurance in developed markets, out-of-pocket costs are still high and act as a barrier for patients. In emerging markets, limited reimbursement policies add to the restrictions on adoption. The high expense also drives demand for biosimilars, but stringent regulation delays their release. Absent widely available cost-effective therapies, affordability will continue to be a key problem for sustainable growth in the hGH market.
Safety Issues and Regulator Restrictions
Safety issues related to long-term use of hGH provide another significant challenge. Possible side effects like edema, arthralgias, enhanced risk of diabetes, and cardiovascular problems evoke concern among physicians and regulators. Secondly, hGH abuse in athletics and bodybuilding has resulted in tight control and surveillance. Bureaucratic barriers to new product approvals combined with sophisticated production processes slow product entry and curtail innovation. These regulatory and safety constraints still hamper the broader implementation of hGH therapies, especially in areas with strict healthcare compliance regulations.
Growth Hormone (GH) Deficiency Market
The market for GH deficiency is one of the largest markets in the human growth hormone arena, fueled by both children and adults in need of long-term therapy. Earlier diagnosis through sophisticated endocrinology testing and genetic testing has enhanced treatment rates. Increasing awareness among parents, physicians, and policymakers has increased access to therapy. Pharmaceuticals are introducing new drug delivery devices to improve compliance in children. Nevertheless, elevated treatment prices and poor affordability in developing countries are challenges. Overall, increasing patient bases and improved diagnostic facilities are driving a steady growth in the GH deficiency segment.
Turner Syndrome Market
The Turner syndrome market is a large area of application for hGH therapy. Turner syndrome is a condition of short stature and delayed puberty in females, in which the use of growth hormone therapy plays a key role. Growing awareness, early detection, and enhanced access to pediatric endocrinologists have fueled treatment uptake. hGH therapy has a dramatic impact on height outcomes, enhancing patients' quality of life. Favorable reimbursement policy in developed nations also supports market growth. Treatment compliance issues and affordability constraints in the growing markets remain, though. With enhanced awareness and diagnostic solutions, the Turner syndrome hGH segment grows steadily.
Human Growth Hormone Hospital Market
Hospitals are a key distribution channel for hGH treatments, particularly among pediatric patients and complicated endocrine diseases. Hospitals offer the facilities for diagnosis, monitoring, and therapy administration, thus playing a key role in the adoption of hGH. Patients typically start treatment within hospital facilities before moving to outpatient treatment. The presence of high-quality injectors, qualified endocrinologists, and robust reimbursement support within hospitals reinforces the channel. Hospitals also have a significant role in clinical trials and the adoption of long-acting formulations. As healthcare infrastructure increases with growing patient populations, hospitals will remain at the forefront of stimulating high growth in the hGH market.
Human Growth Hormone Online Pharmacy Market
Online pharmacy is becoming a rapidly growing sales channel for hGH, fueled by convenience, affordability, and broad accessibility. Consumers with long-term prescriptions increasingly choose home delivery from web-based platforms for competitive prices and subscription refill. Online platforms also give consumers access to educational content, which improves treatment compliance. Expansion is strongest in developed markets where digital healthcare platforms are firmly entrenched. Concerns regarding spurious goods and government restrictions on online sale of prescription medication curbs broader implementation. As electronic healthcare grows worldwide, controlled e-pharmacies will be increasingly involved in hGH distribution.
Intravenous Human Growth Hormone Market
Intravenous (IV) hGH administration is less frequent but utilized in specialized hospital-based environments, such as in acute care or monitored settings. IV administration is suited for rapid absorption and therefore ideal for critical patients who need an instant hormone supplement. Nonetheless, it is not suitable for long-term treatment with regards to invasiveness and patient discomfort. Consequently, its application is limited mostly to hospitals and clinical trials environments. In spite of limited market presence, the IV hGH segment remains significant due to emergency care and specific medical cases. Future technology could make it more relevant, but subcutaneous administration currently prevails.
Subcutaneous Human Growth Hormone Market
Subcutaneous administration is the largest-selling method of delivery for hGH, taking the lion's share of market. It provides convenience, high bioavailability, and compatibility with newer auto-injectors and pen devices. Children and adult patients like subcutaneous injections for long-term therapy as it causes minimal discomfort and is convenient. Pharmaceutical companies are investing in long-acting products for weekly or monthly dosing to further enhance patient compliance. With robust uptake in hospital and homecare environments, subcutaneous delivery is the gold standard for hGH therapy, propelling the segment's ongoing growth worldwide.
United States Human Growth Hormone Market
United States is the largest hGH market, led by sophisticated health care infrastructure, high demand awareness, and extensive insurance coverage. Strong presence of major pharmaceuticals and ongoing R&D efforts in long-acting formulas bolstered market growth. Growing incidence of GH deficiency, Turner syndrome, and adult hormone deficiency drives demand. The U.S. is also a leading center for biosimilar development, driving patient access to cost-effective therapies. Strict regulatory systems surrounding safety and misuse monitoring are challenging but assuring of patient confidence. Pfizer Inc. and OPKO Health Inc. revealed that the FDA approved NGENLA (somatrogon-ghla), a once-weekly human growth hormone analog, for the treatment of pediatric patients three years and older with growth failure resulting from inadequate growth hormone secretion. NGENLA will be available for U.S. prescribing in August 2023.
France Human Growth Hormone Market
France's hGH market is favored by a robust public healthcare system and good reimbursement policies. Pediatric conditions like Turner syndrome and GH deficiency are the biggest drivers of demand. The nation also has an increasing adult population of patients needing hGH therapy for metabolic disorders. France engages actively in clinical research, which drives innovation in drug delivery systems and biosimilars. But strict controls and fears of misuse constrain growth. In spite of this, well-established healthcare infrastructure and government support place France among the strongest hGH markets in Europe.
India Human Growth Hormone Market
The hGH market in India is growing consistently, led by increasing awareness of pediatric growth disorders and improving access to endocrinology treatments. Growth is fueled by a strengthening healthcare infrastructure, rising medical tourism, and availability of affordable biosimilars. While affordability continues to be a challenge for most patients, high treatment expenses and low insurance coverage are keeping them from it. Private hospitals and e-pharmacies are becoming major channels of distribution. Increasing disposable income, urbanization, and government efforts to increase healthcare penetration are likely to drive market uptake. Feb 2025, The Health Minister has announced the introduction of growth hormone (GH) treatment under the State's KARE (Kerala United Against Rare Diseases) scheme, being a big leap in the management of rare diseases on World Rare Disease Day.
Brazil Human Growth Hormone Market
The hGH market in Brazil is expanding as a result of high importance given to pediatric care and government encouragement to the treatment of rare diseases. Government healthcare initiatives typically subsidize hGH treatments for Turner syndrome and GH deficiency, enhancing access among kids. Growing private healthcare adoption and recognition of adult GH shortages are also widening the demand. Yet, other problems like uneven healthcare infrastructure and regulatory delays are constraining faster growth. Jan 2024, With rising investment in biosimilars and growing middle-class populations, Cristalia's growth hormone products have recently been approved for commercialisation in Brazil Ratified by ANVISA1, CRISPEN is part of Nemera's state-of-the-art pen injector platform PENDURA AD.
Saudi Arabia Human Growth Hormone Market
The hGH market in Saudi Arabia is driven by increasing investments in healthcare infrastructure and government focus on improving pediatric and rare disease treatments. Increasing incidence of GH deficiency and Turner syndrome and high disposable incomes are favoring huge demand for hGH drugs. Hospitals are still the key distribution channel, although online pharmacies are becoming significant platforms. Nevertheless, reliance on imported drugs and high expenses of treatment are acting as roadblocks. Government-driven healthcare reforms pursuant to Vision 2030 will further increase access and affordability, making Saudi Arabia one of the quickest-expanding hGH markets in the Middle East.
Market Segmentation
Application
Distribution Channel
Route of Administration
Country
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
All companies have been covered with 5 Viewpoints